መነሻ › ኖን-ስማል ሴል የሳንባ ካንሰር › Ohio › Cincinnati
በCincinnati፣ OH ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች
ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ 35 ጥናቶች በCincinnati እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- The Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Local Institution - 0383, Cincinnati
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Cincinnati Cancer Center, Cincinnati
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- TriHealth Cancer & Blood Institute Research, Cincinnati
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- እና 1 ተጨማሪ
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood · 8 ማይል ርቀት
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- እና 1 ተጨማሪ
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Cincinnati Veterans Affairs Medical Center, Cincinnati
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Cincinnati Medical Center, Cincinnati
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 ማይል ርቀት
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Research Site, Cincinnati
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 ማይል ርቀት
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Research Site, Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Clinical Study Sites, Cincinnati
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- እና 1 ተጨማሪ
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Christ Hospital, Cincinnati
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ተሳታዮችን በመፈለግ ላይደረጃ 3
- USO - Oncology Hematology Care, Cincinnati
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 1
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 1
- St. Elizabeth Healthcare, Edgewood · 8 ማይል ርቀት
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Cincinnati Medical Center, Cincinnati
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
ተሳታዮችን በመፈለግ ላይደረጃ 2
- University of Cincinnati Medical Center, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- University of Cincinnati, Cincinnati
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 1
- The Christ Hospital, Cincinnati
MYLUNG Consortium Part 3: Observational Study
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Christ Hospital Cancer Center, Cincinnati
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 2
- St. Elizabeth Healthcare, Edgewood · 8 ማይል ርቀት
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
ተሳታዮችን በመፈለግ ላይ
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- TriHealth Cancer Institute, Cincinnati
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Research Site 113, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Massive Bio SYNERGY-AI site, Cincinnati
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
ተሳታዮችን በመፈለግ ላይደረጃ 2
- The Christ Hospital, Cincinnati
በሌሎች ከተሞች ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ጥናቶች
- Houston, TX145 ጥናቶች
- New York City, NY120 ጥናቶች
- Arlington, VA104 ጥናቶች
- Nashville, TN97 ጥናቶች
- Boston, MA90 ጥናቶች
- Los Angeles, CA87 ጥናቶች
- St. Louis, MO73 ጥናቶች
- Chicago, IL61 ጥናቶች
- Baltimore, MD60 ጥናቶች
- San Antonio, TX59 ጥናቶች
- Columbus, OH56 ጥናቶች
- Washington, DC55 ጥናቶች
በCincinnati ውስጥ ያሉ ሌሎች ጥናቶች
- ካንሰር (ሁሉም ዓይነቶች)27 ጥናቶች
- የጡንቻ ካንሰር25 ጥናቶች
- የልብ ድካም24 ጥናቶች
- የኮሎሬክታል ካንሰር21 ጥናቶች
- አኩት ማይሎይድ ሊውኬሚያ20 ጥናቶች
- Metastatic Cancer20 ጥናቶች
- የእንቁላል ካንሰር19 ጥናቶች
- የሳንባ ካንሰር19 ጥናቶች
- ከባድ ሰውነት19 ጥናቶች
- የፕሮስቴት ካንሰር18 ጥናቶች
- Multiple Myeloma17 ጥናቶች
- ሜላኖማ17 ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።